Axovant founder and CEO Vivek Ramaswamy has stepped back from the top job, passing the reins to David Hung as the company nears a Phase 3 data readout for its lead Alzheimer's drug candidate.
Pfizer would be acquiring Xtandi, a blockbuster treatment for prostate cancer that is expected to generate annual sales of $1.33 billion by 2020, according to Bloomberg.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
Plus, Bristol-Myers Squibb acquires Comorant Pharmaceuticals, Google's DeepMind gets access to eye scans at British hospital and a court rules that biosimilar makers must notify patent-holders six months before launching competitive products.
Also, one group wants to tap videogamers' expertise to develop a better tuberculosis test and MVM Life Science Partners has closed its fourth fund at $233 million.
Also, Color Genomics expands its genetic test portfolio and Apple rolls out first clinical apps developed with CareKit.
BioMarin Pharmaceutials is selling the global license for its PARP inhibitor talazoparibin to Medivation in a $570 million deal. Hatteras Venture Partners has raised $90 million as part of its first close for its fifth venture fund.
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
LONDON (Reuters) - Britain's healthcare cost watchdog NICE has recommended that a new prostate cancer pill from Medivation and Astellas should be used on the state health service. The draft guidance is conditional on Xtandi being provided at an undiscl...